Clinical trials: Endocrine Therapy
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Diabetes Mellitus, Type 1
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available…
- Trial name
- NCT01994746
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 8 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin
- Trial name
- NCT00860288
- Testing
- Vildagliptin, Metformin, Sitagliptin
- Where
- 187 sites in Argentina, Austria and 19 more
- Volunteers
- 1,988 people
- Sponsor
- Novartis Pharmaceuticals
Premenstrual Syndrome, Menstruation Disturbances
Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder
The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.
- Trial name
- NCT00195559
- Testing
- Levonorgestrel/Ethinyl Estradiol
- Where
- 51 sites in Argentina, Brazil and 10 more
- Volunteers
- 526 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Human Immunodeficiency Virus (HIV) Infections
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for…
- Trial name
- NCT05130086
- Testing
- Islatravir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at…
- Trial name
- SOLO3 (NCT02282020)
- Testing
- OLAPARIB, Single agent chemotherapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318070
- Testing
- Alogliptin and pioglitazone, Pioglitazone
- Volunteers
- 339 people
- Sponsor
- Takeda
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07868354
- Testing
- Tirzepatide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.
Ovarian Cancer
CT-2106 for the Second Line Treatment of Ovarian Cancer
The purpose of this sudy is to determine the response rate of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.
- Trial name
- NCT00291837
- Testing
- CT-2106
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 40 people
- Sponsor
- CTI BioPharma
Hypoparathyroidism
Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults
This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia in adults with hypoparathyroidism.
- Trial name
- NCT06547151
- Testing
- AMOR-1, Crystalline Calcium Carbonate
- Where
- 9 sites in Israel
- Volunteers
- 62 people
- Sponsor
- Amorphical Ltd.
Hypogonadism
A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males
This is an open-label, 2-treatment, 2-period, single dose (200 mg, IM) cross-over study, 2-part design to evaluate the bioequivalence (BE) of a reformulated presentation (test) of testosterone cypionate solution for injection…
- Trial name
- NCT03792477
- Testing
- Test formulation, Reference formulation
- Where
- 2 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, two way crossover, Oral Bioequivalence Study of test product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and…
- Trial name
- NCT07266766
- Testing
- Empagliflozin / Metformin HCl XR Tablets, Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Humanis Saglık Anonim Sirketi
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Ovarian Cancer
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
The purpose of this study was to determine the maximum tolerated dose (MTD)/recommended Phase II dose of lenvatinib administered in combination with carboplatin and gemcitabine (Phase IB) and to evaluate the safety and…
- Trial name
- NCT01133756
- Testing
- Lenvatinib, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eisai Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Type 2 Diabetes Mellitus
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.
- Trial name
- NCT01224366
- Testing
- Vildagliptin
- Where
- 66 sites in Australia, Belgium and 9 more
- Volunteers
- 448 people
- Sponsor
- Novartis
Type 2 Diabetes
A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to…
- Trial name
- NCT00357370
- Testing
- Dapagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals